Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PV-RGDP for Relapsed or Refractory DLBCL
NCT05498220Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 4 months. Started Feb 2023; status: terminated.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05498220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498220.